Frontiers in Public Health
October 6, 2026
Vivian W. L. Tsang, Faizan Bhatia, Anne Ferrey et al.
Background: The group therapy model has been recently favored as a means of conducting psychedelic assisted therapies for mental health disorders. However, there is a paucity of literature showing strengths or drawbacks of this approach and comparisons of safety and efficacy to individual therapy. This systematic review aims to address this gap in literature. Methods: We included original...
Journal of Psychedelic Studies
October 5, 2026
Shannon Dames
Abstract: Background and aims: In Western clinical contexts, dissociation is a common transdiagnostic response to overwhelm and is highly relevant to integration capacity. In psychedelic-assisted therapy (PaT), non-ordinary states may open access to emotionally intense material while also activating protective distance when the experience outpaces coping capacity. This article introduces a...
Psychedelics
October 1, 2026
Maximiliano Zeller
The psychedelic renaissance is routinely presented as a paradigm shift in psychiatric treatment. Yet the research programmes through which psychedelic-assisted therapies are developed and evaluated inherit foundational presuppositions from mainstream psychiatry that are contested within psychiatry and its philosophy. I conduct a philosophical audit of five of them, the nosological,...
Canadian family physician Medecin de famille canadien
October 2026
Daniel Shane, Sabrina Akhtar, Emma Hapke
To review psychedelic-assisted psychotherapy (PAP), including its principles, mechanisms of action, safety considerations, and current state of evidence relevant to Canadian primary care. The evidence of PAP is evolving and is primarily derived from phase 2 and 3 clinical trials in specialized research settings. Systematic reviews and meta-analyses suggest potential benefit for selected...
Journal of Affective Disorders Reports
October 1, 2026
Kevin Byrne, Madeleine Odette, Eric L Garland et al.
ABSTRACT Background Healthcare workers experienced amplified depression and burnout during COVID-19. Both Mindfulness Based Stress Reduction (MBSR) and psilocybin have been shown to reduce depressive symptoms in this population, however the psychological mechanisms by which adding psilocybin to mindfulness training improves depression and trait mindfulness remain incompletely characterized....
Frontiers in Psychiatry
September 21, 2026
Phil Wolfson, Cody Carroll
Introduction Ketamine Assisted Psychotherapy (KAP) is a developing modality with broad impact on humans suffering with a variety of emotional and relationship difficulties that encompass many diagnostic entities. Our application of KAP has extended to and included the treatment of adolescents and young adults in a family therapy format. Given the increasing scope and complexity of the...
npj Mental Health Research
September 16, 2026
Orly Lipsitz, Ryan M Brudner, Zoe Doyle et al.
Cluster B personality disorders (PDs) are highly comorbid with depression and are associated with attenuated antidepressant response. No clinical trials to date have reported on psilocybin-assisted psychotherapy (PAP) in comorbid treatment-resistant depression (TRD) and PDs. This is the first clinical trial to describe a subgroup of ten participants with a comorbid PD ( n = 9 cluster B; n = 1...
Applied Drug Research Clinical Trials and Regulatory Affairs
September 14, 2026
A S Shikha, Jignesh Shah, Darshil B. Shah et al.
Introduction: Psychedelic-assisted therapy has resurfaced as a promising intervention for treatment-resistant psychiatric disorders. However, regulatory pathways differ considerably across countries because of social, ethical, legal, and political factors. Methods: This review was conducted using the regulatory frameworks of Australia, Brazil, and the USA, along with publicly accessible data,...
OSF Preprints
September 10, 2026
Bartosz Helfer, Katarzyna Henke‐Ciążyńska, Daniel Pankowski et al.
preprint
The original data comprise the extraction, coding, identity mappings and appraisals produced for the accompanying meta-research study. Their source material is previously published literature.
The International Journal of Neuropsychopharmacology
September 9, 2026
Katarzyna Henke‐Ciążyńska, Daniel Pankowski, Bartosz Helfer
Abstract Background Systematic reviews with meta-analyses (SR-MAs) of psychedelic-assisted psychotherapy (PAP) guide clinical and policy decisions. Their trustworthiness depends, in part, on how consistently different SR-MAs assess risk of bias (RoB) in the same underlying randomized controlled trials (RCTs), and how transparently those judgments are justified. Aims & Objectives To summarise...